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HCV genotype is a major determinant of clinical outcome, and GT1b HCV infection is the most difﬁcult to
treat and also the predominant genotype in East Asia and Europe. We developed 1b/JFH-1 inter-
genotypic recombinants containing the structural genes (Core, E1, E2), p7 and the 1stTMD of NS2 directly
from GT1b clinical isolates. Through a cloning selection strategy, we obtained 4 functional clones from
3 cases of GT1b patients' sera, which could produce infectious viruses in Huh7.5.1 cells. Sequencing
analysis of recovered viruses from serial passage and reverse genetics revealed that adaptive mutations
in the GT1b-originated region were enough for the enhancement of infectivity. A monoclonal antibody to
E2 and original patient sera could efﬁciently block 3 of the viruses (26C3mt, 52B6mt and 79L9) while had
little effect on 26C6mt viruses. The availability of 1b/JFH-1 chimeric viruses will be important for studies
of isolate-speciﬁc neutralization and useful in evaluating antiviral therapies.
& 2013 Elsevier Inc. All rights reserved.Introduction
About 3% of the world's population is infected with hepatitis C
virus (HCV), and chronic HCV infection is a strong indicator of end-
stage liver disease, such as cirrhosis, liver failure and hepatocel-
lular carcinoma (HCC). No vaccine is available yet. The current
standard treatment, combining pegylated interferon-α and riba-
virin, was recently supplemented with small-molecule inhibitors
targeting HCV encoded NS3/4A serine protease (Sarrazin et al.,
2012). The responsiveness to the therapy is affected by viral and
host factors, including virus genotype, viral load and host genetics
such as single nucleotide polymorphism (SNP) in IL28B loci (Feld
and Hoofnagle, 2005; Ge et al., 2009; Suppiah et al., 2009; Tanaka
et al., 2009).
HCV is an enveloped, positive-stranded RNA virus belonging to
the Flaviviridae family. Its genome is 9.6 kb in length and consists
of a 5′ untranslated region (UTR), an open reading frame (ORF),
and a 3′ UTR. The ORF encodes a single polyprotein, which isll rights reserved.
Vpp, HCV pseudotype parti-
domain; ORF, open reading
hong@sibs.ac.cn (J. Zhong).cleaved into the structural proteins (Core, E1 and E2), p7, and the
nonstructural (NS) proteins NS2, NS3, NS4A, NS4B, NS5A, and
NS5B (Bartenschlager et al., 2004). Due to the rapid replication
rate and poor ﬁdelity of the RNA-dependent RNA polymerase
(RdRp), HCV has a high degree of genetic and antigenic hetero-
geneity with six major genotypes and numerous subtypes. Geno-
types have more than 30% variation at the nucleotide level;
subtypes typically differ from each other by 20–25%. Furthermore,
5–8% sequence divergence is present between individual strains
(variants) of HCV within a given subtype (Simmonds et al., 2005).
In China, Japan and Europe, genotype 1b is the predominant
genotype. With the signiﬁcant variations at the nucleotide and
amino acid levels among HCV genotypes, biological and clinical
differences are expected: Genotype 1b is the least sensitive to
IFNα-based treatment, with the sustained virological response rate
around only 50% (Feld and Hoofnagle, 2005). Meanwhile, HCV
exists in host as quasispecies, which is characterized as a hetero-
geneous population of highly related but genetically distinct
variants and may play a role in disease progression and treatment
response.
The progress in HCV ﬁeld was greatly hindered by the lack of
in vitro culture models until the development of infectious cell
culture systems (HCVcc) based on genotype 2a isolate JFH-1
(Lindenbach et al., 2005; Wakita et al., 2005; Zhong et al., 2005).
Since then, JFH-1-based intra- and inter-genotypic recombinants
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or partial NS2, were developed and efﬁcient growth depended on
various adaptive mutations (Gottwein et al., 2007, 2009; Jensen
et al., 2008; Pietschmann et al., 2006; Scheel et al., 2008; Yi et al.,
2007), allowing the study of vaccines and entry inhibitors for all
genotypes. However, these studies are all based on a few labora-
tory optimized prototype strains (established HCV consensus
molecular clones) (Bukh et al., 2010, 2002; Gottwein et al., 2010;
Kato et al., 2008; Kolykhalov et al., 1997; Lohmann et al., 1999;
Sakai et al., 2007; Yanagi et al., 1997, 1998, 1999). Though the
establishment of these well characterized virus strains has greatly
facilitated the development of new experimental in vitro systems
(Gottwein et al., 2011; Imhof and Simmonds, 2010; Li et al., 2011a,
2011b, 2012b, 2012c; Scheel et al., 2011a, 2011b) and antiviral
therapies, they may not reﬂect the heterogeneous viral population
that exists in HCV-infected patients. No full-length or chimeric
HCVcc system has been developed directly from a clinical isolate.
To investigate the possibility of constructing HCV recombinants
directly from clinical isolates, we selected three Chinese GT1b
hepatitis C patients, ampliﬁed the region harboring Core-1st trans-
membrane domain (TMD) of NS2 from the patient sera, and
construct a library of JFH-1 based recombinants. After transfecting
the library of synthesized chimeric HCV RNA into Huh7.5.1 cells,
we were able to select the cDNA clones from each clinical isolate
that produce infectious viruses in cell culture. The infectivity of
these chimeric viruses can be signiﬁcantly enhanced by contin-
uous passaging of the viruses. Reverse genetic study demonstratedFig. 1. Construction of inter-genotypic 1b/JFH-1 chimeras. (A) Schematic diagram of 1b/JF
(black dotted) was cloned into JFH-1 backbone (white box). The inter-genotypic junction
or at amino acid residues 842/843. (B) Protocol for the construction of infectious 1b/JFHthe mutations in the Core-NS2 (1st TMD) region are responsible
for the enhanced infectivity. These established chimeric HCVcc
displayed different sensitivity to neutralization by an anti-E2
monoclonal antibody or patient sera. Our study not only offers a
new strategy to construct HCVcc directly from clinical isolates, but
also provides a useful tool for the isolate-speciﬁc studies, including
studies of virus assembly, neutralizing antibodies and vaccine
development.Results
Development and cell-culture adaptation of 1b/JFH-1
inter-genotypic recombinants
The recombinant 1b/JFH-1 chimeric virus was constructed in a
manner analogous to that used to generate JC1 (Pietschmann et al.,
2006). The region harboring Core-NS2 (1st TMD) (amino acid 1-
842) (Yamaga and Ou, 2002) was ampliﬁed from HCV patient sera
and used to substitute the JFH-1's counterpart (Fig. 1A). Three
genotype 1b patients (PR26, PR52, PR79) were selected for this
study. Patient sera were collected prior to the interferon therapy,
and HCV RNA levels in the sera were determined (Table 1). The
consensus sequence of the GT1b isolates were obtained by bulk
PCR sequencing of six overlapping fragments (Xiang et al., 2011).
The intact ORFs were assembled and deposited to the NCBI
Genbank with accession number HQ912956 (PR26), HQ912958H-1 chimera. The region harboring Core-1st TMD of NS2 derived from GT1b isolates
is located at nucleotide position 2866/2867 (con1 reference [AJ238799] 2866/2867),
-1 chimeric cDNA clone.
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between GT1b isolates and a reference strain con1 (AJ238799) is
summarized in Table 1 and Supplementary Fig. S1. The sequence
homology of entire ORF or the core-NS2 (1st TMD) region between
PR26, PR52, PR79 and con1 is about 92–93% at the amino
acid level.
The common strategy of constructing inter-genotypic HCV recom-
binants is based on established prototype strains with consensus
sequence. However, the consensus sequence results from the pre-
dominant nucleotide at each position, and may not exist in nature.
Taking this into account, we designed a functional screening strategy
to select the most viable clones from the quasispecies population
(Fig. 1B) instead of using the consensus sequence to make a
prototype cDNA clone by direct DNA synthesis. The Core-NS2 (1st
TMD) PCR ampliﬁcation products, containing a pool of variants, were
fused with JFH-1 backbone. We randomly picked colonies from E. coli
library transformants. After conﬁrming the correct size of the
inserted Core-NS2 (1st TMD) region, we pooled 20–30 clones and
separated them into several groups for HCV RNA synthesis by in vitro
transcription. After transfecting the pools of RNAs into Huh7.5.1 cells,
we passaged the cells and monitored HCV-positive cells percentage
and supernatant infectivity. When a certain group produced detect-
able infectious particles in the culture supernatant, we then repeated
the above experiment to test individual plasmids within this group to
identify the viable candidate(s).
For PR26 and PR52, we transfected 4 groups of RNA transcripts
from a total of 24 plasmids. For PR79, we transfected 6 groups ofTable 1
Similarity between GT1b isolates and con1 reference sequence at amino acid level.
The sequence homology was calculated with BIOEDIT Clustal Multiple Alignment
software.
Patient Id Genotype RNA titer at collection
(IU/mL)
Amino acid identity with con1
(AJ238799) (%)
Core-NS2
(1st TMD)
ORF
PR26 1b 2.7107 93 93
PR52 1b 3.2106 92 92
PR79 1b 4.3106 93 93
Fig. 2. Sequence comparison of core-NS2 (1st TMD) between (A) clone 26C3/26C3mt
consensus sequence and (C) clone79L9 and PR79 consensus sequence. nThe position of aRNA transcripts from a total of 30 plasmids. We could ﬁnd HCV-
positive cells in almost all groups at D2 post-transfection by anti-
NS3 immuno-ﬂuorescence staining (data not shown). We kept
passaging the transfected cells as long as HCV-positive cells were
detected. During the long-term passaging, HCV-positive cells in
most groups became fewer and ultimately disappeared, while in
certain groups HCV-positive cells ﬁnally spread to almost the
entire cell population (over 80%). To identify individual functional
clones responsible for virus expansion, we synthesized HCV RNA
from each plasmid in the selected positive pool, and transfected
them individually into Huh7.5.1 cells. By this way, we selected
2 viable clones from PR26 (named 26C3 and 26C6), 1 from PR52
(named 52B6) and 1 from PR79 (named 79L9). Sequence compar-
ison of these single clones with their consensus sequence from the
original sera is shown in Fig. 2. Clones 26C3 and 26C6 are selected
from the same patient's serum, and only differ in 2 residues in E1
region: at residue 290, 26C3 is Leu while 26C6 is Pro; at residue
364, 26C3 is Thr while 26C6 is Met.
26C3 chimeric virus reached a peak titer of 1.8104 FFU/mL at 74
days post-transfection (DPT); 26C6 had a peak titer of 6.5103
FFU/mL at 74 DPT; the peak infectivity titer of 52B6 was
3.2104 FFU/mL at 41 DPT; 79L9 could produce relatively high titers
of viruses at earlier days after transfection compared with the others:
it was 103 FFU/mL at 5 DPT, and reached the peak titer of 1.3
104 FFU/mL at 21 DPT.
Since it took long time for 26C3, 26C6 and 52B6 to reach the peak
titers, we speculated that the viruses may have acquired adaptive
mutations to enhance the viral infectivity. Thus, we sequenced the
Core-NS2(1st TMD) region of 26C3, 26C6 and 52B6 viruses collected
at their peak titers. In the viral supernatants of 26C3 recovered at 75
DPT, two nucleotide changes were found in E1 and E2 (G1097T and
C1903T), resulting in amino acid change in E1 (V253F) (numbering
throughout is according to the con1 reference sequence AJ238799).
In 26C6, we found two nucleotide changes in E2 and NS2 (G1816A
and A2844G), resulting in amino acid change in NS2 (Y835C)
(Fig. 2A). In the viral supernatants of 52B6 recovered at 39 DPT,
three nucleotide changes occurred in E2 (T1529C, G1533A, and
A1586G) resulting in three amino acid changes (W397R, G398D
and T416A) (Fig. 2B). In the case of 79L9, the infectivity titers at
earlier days post-transfection were high (103 FFU/mL at 5 DPT, and
1.3104 FFU/mL at 21 DPT). It is therefore not surprising that no, 26C6/26C6mt and PR26 consensus sequence, (B) clone 52B6/52B6mt and PR52
mino acid (single-letter code) is according to con1 reference polyprotein sequence.
Fig. 3. Adaptive mutations enhance virus production of the selected clones. (A) In vitro transcribed RNA synthesized from wild-type clones (26C3wt, 26C6wt, 52B6wt and
79L9wt) and clones with adaptive mutations (26C3mt, 26C6mt, 52B6mt) were electroporated into Huh7.5.1 cells. Immuno-ﬂuorescence staining of HCV NS3 protein at day
2 post-transfection showed the transfection efﬁciencies were comparable between the wild-type and mutant RNAs. NS3 staining in green; nuclei stained with Hoechst
(blue). Cell culture supernatants were collected at day 2 (B) and day 7 (C) post-transfection and analyzed for the infectivity titers by a titration assay. (D) Infection kinetics of
adapted viruses. The naïve Huh7.5.1 cells were inoculated with viruses at an moi0.02. Supernatants from the inoculated cells were collected at the time points indicated
and analyzed for infectivity titers as above. 10 FFU/mL is the detection limit.
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noteworthy that other adaptive mutations may exist outside the
region of Core-NS2 (1st TMD) and are beyond of our current study
interest.
Identiﬁcation of adaptive mutations leading to efﬁcient growth
of 1b/JFH-1 viruses
To identify adaptive mutations that are responsible for the
enhanced infectivity, we engineered the non-synonymous amino
acid changes into the original clones, and transfected Huh7.5.1 cells
with the in vitro synthesized RNA of 26C3 wild-type (wt), 26C3-
V253F (26C3mt), 26C6 wt, 26C6-Y835C (26C6mt), 52B6 wt, 52B6-
W397R-G398D-T416A (52B6mt) and 79L9. The anti-NS3 immuno-
ﬂuorescence staining at 2 DPT showed the percentage of HCV-positive cells were comparable among all groups, indicative of similar
transfection efﬁciencies (Fig. 3A). At day 2 and day 7, the cell culture
supernatants were collected and infectivity was measured (Fig. 3B,
C). Adaptive mutations greatly enhanced the virus titers: the V253F
mutation enhanced the infectivity titers of 26C3 virus at 2 DPT for 78
folds; the Y835C mutation enhanced the infectivity titers of 26C6
virus at 2 DPT for 43 folds; the three mutations W397R-G398D-
T416A introduced to the N-terminus of its E2 protein of 52B6 virus
enhanced the infectivity titers at 7 DPT for 342 folds. 79L9 had an
infectivity of 610 FFU/mL and 3700 FFU/mL at 2 DPT and 7 DPT,
respectively. Direct sequencing of the intracellular HCV RNA con-
ﬁrmed no other mutations occurred at 7 DPT (data not shown).
Next we compared the growth kinetics of these rescued
1b/JFH1 viruses. Naïve Huh7.5.1 cells were infected at low multi-
plicity of infection (moi∼0.02) with viral supernatants collected from
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as a positive control (Fig. 3D). The culture supernatants at the various
days post infection were collected for measuring the infectivity titers.
For 52B6mt and JFH1, the infectivity plateaued on 7 days post
infection (DPI) and the titers were over 105 FFU/mL. Due to severe
cytopathological effect, we could not continue the passage of JFH-1
and 52B6mt after 9 DPI. 26C3mt and 26C6mt propagated more
slowly than 52B6mt, both of which had titers of around 103 FFU/mL
at 7DPI and ﬁnally reached peak titers of above 104 FFU/mL at 15 DPI
(26C3mt) and 12 DPI (26C6mt), respectively. 79L9 had an eclipse
phase before achieving titers of over 103 FFU/mL at 15DPI.Fig. 4. The infection of Huh7.5.1 cells with HCVpp bearing the E1–E2 regions of
26C3wt, 26C3mt, 26C6wt, 52B6wt, 52B6mt and 79L9 clones. H77 and env- was
positive and negative controls, respectively. HCVpp produced from transfection of
HEK293T cells were used to infect Huh7.5.1 cells for 3 days. The lysates of infected
cells were assayed for the luciferase activities. The error bar represented triplicates.
Fig. 5. Mean7SE neutralization of 1b/JFH-1 viruses by E2 monoclonal antibody. (A) Al
regions important for E2 binding with its monoclonal antibody (AR3A clone) (Law et al.
79L9 clones were aligned. (B) 250 FFU viruses were incubated with serial 5-fold dilutio
pre-seeded in 48-well plate for 3 days. The intracellular HCV RNAwas quantiﬁed by RT-q
performed twice and representative data were shown. The error bars indicate standardPseudotype retroviral particles bearing the HCV envelope glyco-
proteins (HCVpp) have provided a practical approach to HCV entry
studies. To test whether adaptive mutations enhanced the infectivity
by improving the entry efﬁciency of HCV particles, we compared the
infection of HCVpp bearing the wild type or mutant E1–E2 sequence
(Fig. 4). For 26C6, since the mutation is located in the NS2 protein, the
HCVpp bearing E1–E2 from 26C6wt and 26C6mt is identical and thus
only 26C6wt was included in the HCVpp assay. H77 (GT1a reference
clone, GenBank AF009606) E1–E2 and env- served as positive and
negative controls for the experiment, respectively. As shown in Fig. 4,
the infection of HCVpp bearing the envelope proteins of 26C3wt,
26C3mt, 26C6wt and 79L9 was similar to that of the env- negative
control, suggesting these envelope proteins are not functional in the
context of HCVpp infection. However, the three mutations in its N-
terminus of E2 (W397R, G398D and T416A) in 52B6 greatly enhanced
the HCVpp infection, indicating these mutation may improve the
HCV entry efﬁciency.
Blockade of 1b/JFH-1 viruses by anti-E2 neutralizing antibody
The existence of broadly conserved neutralizing antibodies to HCV
has been conﬁrmed with HCVpp (Bartosch et al., 2003). These
antibodies differ in their breadth and mechanism of neutralization
(Edwards et al., 2012). To investigate whether the 1b/JFH-1 chimeric
viruses could be blocked by neutralizing antibodies, we performed the
neutralization assay with a previously reported human anti-E2
monoclonal antibody (clone AR3A) (Law et al., 2008). Due to the
low infectivity of 26C3, 26C6 and 52B6 wild-type viruses, we used the
mutant virus with the adaptive mutations to perform this assay. HCV
E2 protein has been reported to contain 3 discontinuous regions
(residues 396–424, 436–447, 523–540) important for the binding with
its monoclonal antibody AR3A (Law et al., 2008). The sequence
comparison of the E2 epitopes between 26C3mt, 26C6mt, 52B6mt,
79L9 and H77 reference strain is shown in Fig. 5A. For the neutraliza-
tion assay, the infectious HCV supernatants were pre-incubated withignment of deduced E2 epitopes. The residues 396–424, 436–447 and 523–540 are
, 2008). The corresponding amino acids sequence of 26C3mt, 26C6mt, 52B6mt and
ns (1:20–1:2500) of E2 monoclonal antibody for 1 h and then infected Huh7.5.1 cells
PCR and expressed as the percentage of the culture medium control. Each assay was
deviation from the mean.
Fig. 6. Neutralization of a panel of viruses by PR26, PR52, PR79 and control sera: (A) JFH-1 viruses; (B) 26C3mt viruses; (C) 26C6mt viruses; (D) 52B6mt viruses; and (E) 79L9
viruses. 250 FFU viruses were incubated with serial 5-fold dilutions (1:100–1:12,500) of each serum prior to inoculation into Huh7.5.1 cells. The intracellular HCV RNA was
quantiﬁed by RT-qPCR and expressed as the percentage of the control serum of the same dilution. The error bars indicate standard deviation from the mean.
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Huh7.5.1 cells. The neutralization of HCV infection was measured by
intracellular HCV RNA levels. As shown in Fig. 5B, the HCV infection of
JFH-1, 52B6mt, 79L9 viruses was efﬁciently inhibited by pre-
incubation with the anti-E2 antibody in a dose-dependent manner.
For JFH-1, a 90% inhibitionwas observed at 1:500 dilution of anti-E2
antibody. For both 52B6mt and 79L9 virus, a 490% inhibition was
achieved with 1:500 dilution of anti-E2 antibody. 26C3mt virus was
moderately inhibited by the anti-E2 antibody: about 70% of virus was
neutralized at 1:100 dilution of anti-E2 antibody. As for 26C6mt virus,
the anti-E2 antibody had barely any effect on its infection: even at the
highest concentration of E2 antibody (1:20), 70% of the virus infection
remained. Given the fact that the E2 sequence of 26C3mt and 26C6mt
is identical (Figs. 2A and 5A), it is intriguing to study the mechanism
underlying the difference in their sensitivity to E2 antibody.
Neutralization of 1b/JFH-1 viruses by GT1b patient sera
We investigated whether the GT1b sera where the structural
proteins were originally derived from could neutralize the homo-
logous or heterologous 1b/JFH-1 virus. We ﬁrst used JFH-1 virus to
test whether the patient sera contained neutralizing antibodies.As shown in Fig. 6A, the neutralizing ability in the patient sera
against JFH-1 virus was different: we observed a 450% inhibition of
JFH-1 infection by PR26 serum at 1:500 dilution, by PR52 serum at
1:2500 dilution and by PR79 serum at 1:12,500 dilution, which
indicated the PR79 serum had the highest neutralizing activity. Next
we tested how these patient sera neutralized the 1b/JFH-1 viruses.
26C3mt virus can be blocked by the sera of PR26, PR52 and PR79 in a
dose-dependent manner (Fig. 6B). With a 1:500 dilution of PR26
serum, 1:500 dilution of PR52 serum and 1:2500 dilution of PR79
serum, the neutralization of 26C3mt virus was about 40%, 30% and
30%, respectively. 26C6mt virus is very unique in that it cannot be
neutralized by any patient sera at even the highest serum dosage
(Fig. 6C). 52B6mt virus and 79L9 virus are both sensitive to patient
sera treatment (Fig. 6D, E): at 1:12,500 dilution of PR26 serum and
PR52 serum, 450% inhibition of both viruses were observed. When
using PR79 serum to neutralize 52B6mt virus and 79L9 virus, 490%
inhibition was observed at 1:12,500 dilution.
Discussion
JFH-1 based intra- or inter-genotypic recombinant viruses have
been constructed with well characterized prototype strains
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(S52, 452, DBN), 4a (ED43), 5a (SA13), 6a (HK6a), 7a (QC69))
(Gottwein et al., 2007, 2011, 2009; Imhof and Simmonds, 2010;
Jensen et al., 2008; Li et al., 2011; Lindenbach et al., 2005;
Pietschmann et al., 2006; Scheel et al., 2011, 2008; Yi et al.,
2007). Most of the prototype strains have been optimized and
validated functional in vivo (Bukh et al., 2010).
To develop novel cell culture system for uncharacterized
clinical HCV variants is still of few reports. The common way is
to generate a consensus sequence from hepatitis C patient serum
and construct cDNA clone by in vitro DNA synthesis, the infectivity
of which usually relies on adaptive mutations (Scheel et al., 2011).
Single-genome sequencing results revealed enormous genetic
diversity of HCV quasispecies in chronically infected subjects (Li
et al., 2012a). How to make a representative master sequence for
these subjects will be of difﬁculty. Thus, the use of a consensus
sequence for cell culture model without validation of function
in vivo is of high risk.
To overcome the obstacle, we designed a functional screening
method to select viable clones from a pool directly constructed
from patient sera. We have identiﬁed clones 26C3 and 26C6
from PR26-origin serum, clone 52B6 from PR52-origin serum
and clone 79L9 from PR79-origin serum, all of which could
produce infectious virus albeit at a low efﬁciency. Passage of the
viruses enhanced the infectivity titers, and reverse genetic studies
showed that 26C3-V253F, 26C6-Y835C, 52B6-W397R/G398D/
T416A yielded robust production of infectious viruses (Fig. 3B, C).
It is interesting to note that most of these mutations are found
within the structural proteins. This is in contrast to the reported 1b/
JFH-1 chimeric viruses J4/JFH-1 (Gottwein et al., 2009), DH-1/JFH-1
and DH5/JFH-1 (Scheel et al., 2011), all of which need adaptive
mutations in JFH1's non-structural proteins. It is still possible that
we may have missed some mutations in JFH-1-origin sequence
since we only sequenced the ﬁrst 842 residues of 1b-origin,
although this possibility seems slim given the observations that
the recombinant chimeric viruses containing only these mutations
in the 1b-origin region can almost recapitulate the phenotype of
the adapted viruses in which these mutations were identiﬁed.
The retroviral HCVpp system could be used to study HCV entry
in a single round infection (Bartosch et al., 2003; Drummer et al.,
2003; Hsu et al., 2003). To our surprise, 26C3wt, 26C3mt, 26C6wt
and 79L9 had similar entry efﬁciency as the env- control; the only
improvement was observed in 52B6mt: it had more than 1 log
increase in luciferase activity compared with 52B6. This result
suggests that HCVpp may not be an ideal in vitro system to study
HCV entry because HCVpp lacks lipoprotein association, an impor-
tant character found in HCVcc and clinical HCV isolates.
Sequence comparison between con1, 26C3, 26C6, 52B6 and
79L9 showed the highest heterogeneity in the N-terminus of E2
protein (data not shown). When we used an E2 monoclonal
antibody to check its neutralizing effect against 26C3mt, 26C6mt,
52B6mt and 79L9 viruses, an efﬁcient inhibition of 52B6mt and
79L9 infection was observed, while 26C3mt viruses were less
responsive and 26C6mt viruses were almost resistant to AR3A
neutralization (Fig. 5B). Since 26C3mt and 26C6mt have identical
E2 sequence, their different susceptibility to the neutralization
might be due to the altered epitope conformations or exposure.
Our previous studies showed that a single-point mutation in E2
could reduce the association of viral particles to host lipoproteins,
exposing the epitopes on the viral glycoproteins to neutralizing
antibodies (Grove et al., 2008; Tao et al., 2009). It would be
interesting to test whether 26C3mt and 26C6mt viruses have a
different lipoprotein association. We found that these two viruses
had different buoyant density distribution proﬁles in the sucrose
gradient ultracentrifugation assay (data not shown). The infectiv-
ity of 26C6mt was enriched in lower density fractions comparedwith that of 26C3mt virus. Further studies are needed to investi-
gate whether and how this altered density distribution contributes
to the neutralization sensitivity.
In summary, we have developed a method to construct inter-
genotypic 1b/JFH-1 viruses directly from clinical isolates using
functional cloning and selection strategy. A total of 4 chimeric
viruses have been constructed. Infectivity can be improved by
adaptive mutations. Recombinant viruses with adaptive mutations
in the Core-NS2 region yielded infectivity titers of above 104 FFU/
mL. Infection with these viruses was inhibited by pre-incubation
with anti-E2 monoclonal antibody or genotype 1b patient sera to
different extent. The availability of 1b/JFH-1 viruses from clinical
strains not only permits an effective tool in screening drug
candidates, but also enables isolate-speciﬁc studies for virus
assembly and neutralizing antibodies.Materials and methods
Source of HCV and patient serum
The sources of the genotype 1b isolates PR26, PR52 and PR79
were three hepatitis C patients who received the treatment of Peg-
IFN-α plus Ribavirin from July 2007 to July 2008 at the Department
of Infectious Diseases of Ruijin Hospital, Shanghai Jiaotong Uni-
versity School of Medicine. The study was approved by the Ethics
Committee of Shanghai Ruijin Hospital in accordance with the
Helsinki Declaration, and written informed consents were
obtained from all patients. HCV RNA quantiﬁcation was performed
using a one-step quantitative HCV RT-PCR kit (PG Biotech, Shenz-
hen, China). HCV genotyping was performed using the HCV
genotyping gene chip kit (Realchip Biotech, Ningbo, China) accord-
ing to the manufacturer's instructions. The HCV RNA titers of the
3 patients are listed in Table 1.
HCV ORF ampliﬁcation and sequence determination
The ampliﬁcation and sequence determination of GT1b HCV
isolates was based on serum from treatment-naïve state. The HCV
consensus genome was ampliﬁed by nested RT-PCR with primers
described as described elsewhere (Xiang et al., 2011; Yao and Tavis,
2005). Brieﬂy, total RNA was extracted from 140 μl of serum
samples, using QIAamp Viral RNA mini kit (QIAGEN, Hilden,
Germany), and dissolved in 40 μl of nuclease-free water and stored
at −80 1C until use. HCV RNA was reverse-transcribed (RT) into
cDNA using TaKaRa AMV XL reverse transcriptase (TaKaRa, Dalian,
China) with HCV speciﬁc primers. HCV cDNA was divided into six
overlapping fragments and ampliﬁed by RT-PCR. All ampliﬁed
products were puriﬁed and sequenced directly. The consensus
sequence of HCV ORF was obtained by aligning overlapping
sequences of PCR products. A total of three HCV genotype 1b
sequences generated in this study have been deposited in Gen-
Bank under the accession numbers of HQ912956 (PR26),
HQ912958 (PR52) and HQ912959 (PR79), respectively. Sequence
homology of these genomes with con1 reference sequence
(AJ238799) is listed in Table 1.
Construction of JFH-1-based inter-genotypic recombinants
and HCVpp genesis
The HCV region covering Core-NS2 (1st TMD) was ampliﬁed by
RT-PCR from patient serum RNA and then fused with 5′UTR and
remaining NS2 to NS3 from JFH-1 by overlapping PCR. This fusion
PCR product was digested by EcoR I and Spe I and then ligated into
pUC-vJFH-1 plasmid. The randomly-selected and sequence-
conﬁrmed correct clones were divided into 4–6 groups (with each
J. Lu et al. / Virology 443 (2013) 80–88 87group containing 6–8 plasmids) and plasmids in each group were
pooled together for HCV RNA synthesis and transfection as
described previously (Zhong et al., 2005). After transfection, the
HCV expression was monitored by NS3 immuno-ﬂuorescence
staining and supernatant infectivity. When most of the cells were
infected (≥80% HCV-positive cells of total population) we stopped
passage and sequenced the region of Core-NS2 (1st TMD) from cell
culture supernatants. Then we individually transfected clones that
had the highest sequence identity with the supernatant HCV
sequence. If adaptive mutations in Core-NS2 (1st TMD) region
occurred, we engineered mutations back into the parental clone by
point mutation with Quick Change II XL Site-Directed Mutagenesis
Kit (Stratagene). Primers for the Core-NS2 ampliﬁcation and fusion
PCR are listed in Supplementary Table S1.
To make the HCV E1–E2 expression constructs for HCV pseu-
dotype particles (HCVpp), the E1 and E2 sequences were ampliﬁed
by PCR from wild-type or mutant 1b/JFH-1 chimeric constructs
and inserted into the Kpn I and EcoR I sites of pCDNA3.1. H77 E1–E2
was sub-cloned similarly as positive control for HCVpp assay.
Empty vector was included as negative control (envelop−, env−).
Final DNA stocks were prepared with Tiangen Plasmid Mini kit and
the HCV sequence was conﬁrmed by sequencing. HCVpp were
generated as previously described (Tao et al., 2009). Brieﬂy, 293T
cells were transfected with expression vectors encoding the HCV
E1 E2, retroviral Core packaging component, and luciferase. The
medium was replaced 6 h after transfection. Supernatants were
harvested 48 h later, ﬁltered through 0.45 μm-pore membranes,
and used to infect Huh7.5.1 cells, which had been seeded the day
before at a density of 1104 cells per well in 96-well plate. Three
days later, the Huh7.5.1 cells were lysed and measured for
luciferase activity (Promega).
HCV cell culture, RNA transfection and immuno-staining
The cell culture conditions and protocols for in vitro transcrip-
tion and HCV RNA electroporation have been described previously
(Zhong et al., 2005). Anti-NS3 immuno-ﬂuorescense staining was
done with mouse anti-HCV NS3 protein monoclonal antibody
(Abmart, Shanghai, China) as primary antibody and Alexa Fluor
488 goat anti-mouse IgG (Invitrogen) as secondary antibody.
Neutralization of virus infection with E2 antibody or patient serum
Approximately 250 focus-forming-units (FFU) viruses were
incubated for 1 h at 37 1C with serial dilutions of heat-
inactivated (56 1C for 30 min) patient sera, healthy control serum
or anti-E2 monoclonal antibody (AR3A) (Law et al., 2008) in ﬁnal
dilutions as indicated. The virus-serum mixture was added to
2104 of pre-seeded Huh7.5.1 cells in each well of 48-well plate
and incubated for 3 days. The efﬁciency of infection was deter-
mined by quantitative RT-PCR analysis. The percentage of neutra-
lization for each serum sample was calculated by comparison with
the control serum of the same dilution. The percentage of
neutralization of anti-E2 antibody was compared with the cell
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